That is looking very likely, but the spodumene market might see a slight improvement in 2020. Depends on which analyst you believe. Anyway, I'm giving them at least two more quarters to see if they can reduce costs, if not I will drop PLS from my portfolio. It is looking increasingly likely that the company will fail and the Chinese/CATL will take the asset.
That is looking very likely, but the spodumene market might see...
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.11 |
Change
-0.205(6.19%) |
Mkt cap ! $9.441B | |||
| Open | High | Low | Value | Volume |
| $3.20 | $3.22 | $3.09 | $324.9M | 102.4M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 257083 | $3.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.11 | 102543 | 31 |
View Market Depth
| Last trade - 11.54am 03/10/2024 (20 minute delay) ? |
| PLS (ASX) Chart |